Beetroot Dosing Protocol
TL;DR
Performance: 70–140 mL beetroot juice (~300–500 mg nitrate) taken 2–3 hours pre-exercise. Blood pressure: 250 mL/day (~70 mmol nitrate/L) or 70 mL concentrated shot 1–2× daily, morning fasted. Cycling: 5 days on / 2–3 days off to mitigate nitrate tolerance. Avoid: antiseptic mouthwash 24–48 h around dosing. Screen for: PDE5 inhibitors, organic nitrates (contraindicated), antihypertensives (monitor BP), kidney stone history, G6PD deficiency.
Dosing Formats
| Format | Dose | Nitrate | Bioavailability | Notes |
|---|---|---|---|---|
| Beetroot juice (fresh/frozen) | 70–140 mL | ~300–620 mg | ~90–100% | Highest quality evidence; perishable; taste is the main compliance barrier |
| Beetroot juice concentrate shot | 30–50 mL | ~300–500 mg | ~90–100% | Higher concentration per mL; equivalent PK to juice |
| Beetroot powder (freeze-dried, encapsulated) | As labeled | ~300–500 mg | ~70–85% | Long shelf life; verify nitrate content via Certificate of Analysis (CoA) |
| Sodium/potassium nitrate solution | Calculated | 300–500 mg | ~95–100% | Precise dosing; less outcome data than beetroot; regulatory uncertainty |
| Beetroot extract (solid tablet/capsule) | Variable | Often underdosed | Variable | Quality control is the primary concern — many products deviate 30–70% from labeled content |
Avoid enteric-coated formulations — these bypass the oral conversion step, eliminating the vascular benefit mechanism.
Timing
| Goal | Timing | Rationale |
|---|---|---|
| Exercise performance | 2–3 h pre-exercise | Peak plasma nitrate (Tmax ~1–2 h); window covers warm-up and early exercise |
| Blood pressure (chronic) | Morning fasted | 2–4 h peak aligns with morning BP surge; consistent daily timing for trend tracking |
| Both goals | AM fasted dose + separate 2–3 h pre-exercise dose | Split approach; caution on total daily nitrate — do not exceed ~600 mg startup without monitoring |
Cycling Protocol
Nitrate tolerance develops after 7–14 days of continuous high-dose supplementation. Without cycling, the BP-lowering effect attenuates substantially.
Recommended cycling schedule:
| Schedule | On | Off | Notes |
|---|---|---|---|
| 5 on / 2 off | Monday–Friday | Saturday–Sunday | Standard; works well for most users |
| 7 on / 3 off | 1 week | 3 days | More conservative; better for users with strong tolerance signal |
| 5 on / 2–3 off | Monday–Friday | Saturday–Sunday (+ Monday) | Preferred for Vitals coaching; allows weekly trending on consistent days |
Evidence gap: Optimal cycling frequency is mechanistically justified but has not been formally tested in RCTs. The recommendation is based on PK/PD logic and the known 7–14 day tolerance onset.
Mouthwash Protocol
Antiseptic mouthwash (chlorhexidine gluconate, cetylpyridinium chloride) kills the oral nitrate-reducing bacteria required for the entero-salivary pathway.
Required behavior:
- Stop: Discontinue antiseptic mouthwash 24–48 h before beetroot dosing
- Avoid during cycle: Do not use chlorhexidine or CPC rinses on beetroot supplementation days
- Alternative: Use non-antiseptic fluoride toothpaste and alcohol-free, non-antibacterial mouthwash during beetroot cycles
- If medically necessary: Accept that beetroot benefit will be significantly reduced; discuss with prescribing clinician
Drug Interaction Screening Summary
RED — Contraindicated (Do Not Proceed Without Physician Consultation)
| Drug | Reason |
|---|---|
| PDE5 inhibitors (sildenafil/tadalafil/vardenafil) | Additive NO-cGMP amplification → severe hypotension, syncope, MI, stroke |
| Organic nitrates (nitroglycerin, isosorbide dinitrate, isosorbide mononitrate) | Same nitrate-nitrite-NO pathway; synergistic vasodilation |
AMBER — Use With Caution and Monitoring
| Drug Class | Recommendation |
|---|---|
| Antihypertensives (ACE-I, ARBs, beta-blockers, CCBs, thiazides) | Start with lower beetroot dose (70 mL, not 140 mL). Monitor morning BP for 1 week after initiating beetroot. Advise patient to report lightheadedness, dizziness, or syncope. Coordinate timing with prescribing physician. |
| SSRIs | Impaired methemoglobin reductase activity → elevated methemoglobinemia risk with high-dose nitrate. Watch for cyanosis, headache, chocolate-brown blood. Not an absolute contraindication but requires vigilance. |
LOW — Partial Efficacy Reduction Only
| Drug / Behavior | Effect | Recommendation |
|---|---|---|
| PPIs / H2 blockers | Reduce gastric acid → modest reduction in non-enzymatic nitrite-to-NO conversion; pathway largely intact | Monitor for reduced response; not dangerous |
| Antibiotics | Broad-spectrum antibiotics suppress oral nitrate reducers; 2–4 week recovery | Retest pathway function after antibiotic course; rebaseline before expecting full beetroot effect |
| Low-nitrate diet baseline | Background vegetable intake confounds crossover designs | Advise consistent dietary nitrate intake or record 24 h dietary recall at baseline visits |
Safety Flags
Oxalate / Kidney Stones
Beetroot contains oxalate (~150–200 mg/100g). At high chronic doses (>500 mL/day), oxalate load may increase calcium oxalate stone risk in recurrent stone formers.
Mitigation: Adequate hydration; consider lower doses (70 mL rather than 140 mL); monitor for hematuria or stone recurrence in history-positive patients.
Methemoglobinemia
Rare but possible in:
- G6PD deficiency — theoretical risk; monitor SpO₂
- SSRIs — impaired methemoglobin reductase
- Gastric surgery patients — altered nitrite metabolism
Signs: Cyanosis, headache, chocolate-brown blood (dark venous blood). If observed, discontinue and seek medical evaluation.
SpO₂ monitoring: Routine monitoring not required in healthy users. Monitor only in at-risk populations (G6PD deficiency, concurrent SSRI use, known nitrate sensitivity).
Hypotension
Active hypotension (SBP <90 mmHg) or orthostatic hypotension is a contraindication. Beetroot can exacerbate low BP, especially when combined with antihypertensives.
Special Populations — Excluded or Unstudied
- Pregnant/lactating women: Safety not established; exclude from protocols
- Children/adolescents: No systematic safety or dosing data
- Severe CKD (eGFR <30): Impaired renal nitrate clearance; potassium content (~250–300 mg/100g) relevant for hyperkalemic CKD
- End-stage heart failure (NYHA III–IV): Unstudied; hemodynamics may be compromised
- Critical limb ischemia (Fontaine III–IV PAD): Unstudied; potentially highest-risk population
Protocol Summary
| Parameter | Recommendation |
|---|---|
| Format | Beetroot juice (fresh/frozen) preferred; powder acceptable with CoA verification |
| Performance dose | 70–140 mL (~300–500 mg nitrate), 2–3 h pre-exercise |
| BP dose | 250 mL/day or 70 mL concentrate shot 1–2× daily, morning fasted |
| Cycle | 5 days on / 2–3 days off |
| Mouthwash | Stop antiseptic rinses 24–48 h before beetroot; avoid during cycle |
| RED drugs | PDE5i, organic nitrates — contraindicated; do not proceed |
| AMBER drugs | Antihypertensives — start low (70 mL), monitor BP week 1; SSRIs — vigilance for methemoglobinemia signs |
| Safety | Kidney stone history → hydrate + lower dose; G6PD/SSRI → monitor SpO₂; hypotension → contraindicated |
| Expected peak | 2–4 h post-dose for BP; acute performance window ~2–6 h |
| Evidence gap | Cycling protocol not formally tested; non-responder identification not possible without microbiome testing |
Related Notes
- Beetroot Nitrate — hub note; full mechanism, evidence, comparative supplements, risks, stack context
- Blood Pressure Response Nitrate — biometrics note; measurement protocol, confounders, wearable interpretation
- Vitals Knowledge Map — vault topic index